Phase I study finished

We have completed phase I study with JAK kinase inhibitors.

The JAK family of non-receptor tyrosine kinases regulates the transduction of signals from cytokines and their receptors by activating STAT transcription factors and modulating the expression of STAT-dependent genes. Excessive activation of the JAK/STAT pathway has been confirmed in immune-related diseases, where JAK kinases participate in the induction and maintenance of inflammation. The development of therapy based on the inhibition of JAK family kinases has applications in many areas: oncology by inhibiting excessive cell growth and proliferation (e.g. JAK2 inhibitor in myeloproliferative syndromes and leukemias), in immunology by regulating the secretion of pro-inflammatory cytokines (e.g. JAK1 inhibitor in chronic lung diseases inflammatory) and in transplantology due to its immunosuppressive effect (inhibition of JAK3 kinase). 

The study was performed with healthy volunteers in two parts: A (single ascending dose) and B (multiple ascending dose), with different doses and placebo control.

Go back

News

6th anniversary

This week we celebrate our 6th anniversary. Together with our CEO, clinical team and company's friends, we had a pleasure of being at Aga Zaryan's concert and fancy diner.

Read more …

Webinar

We are constantly improving our knowledge to assure the best possible quality of our services.

Read more …

Medical Guide Where to Treat 2022

On 29th of April, a special thematic supplement was published in the Polska The Times and Miasto.pl newspaper - Medical Guide Where to Treat 2022...

Read more …

BRG Support for Ukraine

We are deeply moved and concerned by the events in Ukraine. As a clinical site, focused on the development of medicine and helping other people,...

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲